CAMBRIDGE, Mass., Nov. 28, 2016 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (Nasdaq:CLCD), a biopharmaceutical company that is developing lasmiditan oral tablets for the acute treatment of migraine in adults, with or without aura, announced today it will provide a corporate overview at the 28 th Annual Piper Jaffray Healthcare Conference, being held on November 29-30 in New York City.
About CoLucid Pharmaceuticals, Inc. CoLucid is developing lasmiditan oral tablets for the acute treatment of migraine headaches in adults and intravenous lasmiditan for the acute treatment of headache pain associated with migraine in adults in emergency room and other urgent care settings.
|28 th Annual Piper Jaffray Healthcare Conference|
|Date:||Wednesday, November 30|
|Time:||1:00 pm Eastern Time|
|Location:||The Lotte New York Palace Hotel, Holmes I Room|
CONTACTThomas MathersChief Executive OfficerCoLucid Pharmaceuticals, Inc.(857) 285-6494Hans VitzthumManaging DirectorLifeSci Advisors, LLC.(212) 915-2568